Form 4: Artiva Biotherapeutics COO Exchanges Options for RSUs

Artiva Biotherapeutics' COO, Jennifer Bush, exchanged existing employee stock options for 84,877 restricted stock units on December 12, 2025.

Summary

• Jennifer Bush, COO, CLO, Secretary, and Compliance Officer of Artiva Biotherapeutics, Inc. (ARTV), engaged in an option exchange on December 12, 2025.
• Bush acquired 84,877 shares of Common Stock in the form of Restricted Stock Units (RSUs) under the Issuer's 2024 Equity Incentive Plan.
• In exchange for the RSUs, four tranches of employee stock options were cancelled, totaling 84,879 options.
• The cancelled options had exercise prices ranging from $5.01 to $13.47.
• Following the transaction, Bush directly beneficially owns 232,925 shares of Common Stock and no derivative securities.

Sentiment

Score: 6

Explanation: The transaction is a standard equity compensation event, reflecting an internal restructuring of executive incentives. The grant of RSUs is generally positive for aligning management with shareholder interests, though the cancellation of options could be viewed neutrally or slightly negatively depending on the stock's future performance relative to the original strike prices.

Positives

• The grant of Restricted Stock Units (RSUs) aligns management's long-term interests with those of shareholders, as RSUs typically vest over time and gain value with stock price appreciation.
• The transaction simplifies the equity compensation structure for the reporting person by converting options into RSUs.

Negatives

• The cancellation of existing stock options means the reporting person foregoes potential upside if the stock price were to significantly exceed the original option exercise prices.
• The exchange effectively resets the strike price to $0 for the new RSU grant, which could be seen as dilutive if not properly managed within the overall compensation plan.

Risks

• Equity compensation plans, including RSU grants, can lead to dilution for existing shareholders if not managed carefully.
• The value of the RSUs is directly tied to the company's stock performance, exposing the recipient to market volatility.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the vesting schedules of the previously held options and the implied future vesting of the newly granted RSUs.

Industry Context

Option exchanges and RSU grants are common practices in the biotechnology and pharmaceutical industries to incentivize and retain key executives, aligning their compensation with long-term company performance and shareholder value creation. This transaction reflects a standard approach to equity compensation management.

Comparison to Industry Standards

• Equity compensation, including stock options and restricted stock units, is a standard component of executive compensation packages across the biotechnology sector, similar to practices at companies like Moderna, BioNTech, or Gilead Sciences.
• Option exchange programs are occasionally utilized by companies to re-align executive incentives, particularly when stock prices have fallen below previous option strike prices, making existing options less effective as retention tools. This is a recognized strategy, though its frequency varies by market conditions and company-specific performance.
• The grant of RSUs at a $0 exercise price is typical for such awards, as their value is derived from the underlying stock price at vesting, rather than an exercise event.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns management's incentives with shareholder value creation. However, equity compensation can lead to dilution over time.
• Employees: This transaction specifically impacts a key executive's compensation structure.

Next Steps

• The newly acquired Restricted Stock Units (RSUs) will vest according to their specific schedule, which is not detailed in this filing but is implied by the grant.
• Jennifer Bush will continue to file Form 4s for future changes in her beneficial ownership of Artiva Biotherapeutics securities.

Key Dates

Recommendation

This Form 4 filing details a routine insider equity compensation event (an option exchange for RSUs) and does not contain information that would fundamentally alter the investment thesis for Artiva Biotherapeutics. It is a standard disclosure and does not provide new insights into the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation.

Keywords

Artiva Biotherapeutics, ARTV, Jennifer Bush, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Option Exchange, Corporate Officer